Regenerative Stromal Cell Therapy in Allogeneic Hematopoietic Stem Cell Transplantation: Current Impact and Future Directions

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 7, 2010, Pages 891-906

  Auletta, Jeffery J ^a,b   Cooke, Kenneth R ^a,b   Solchaga, Luis A ^b   Deans, Robert J ^b   van't Hof, Wouter ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; Immunomodulation; Mesenchymal stem cell; Microenvironment; Multipotent adult progenitor cell; Rgenerative stromal cell therapy

Indexed keywords

CHEMOKINE; CYTOKINE; IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STEROID; TOLL LIKE RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ADAPTIVE IMMUNITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DENDRITIC CELL; ENGRAFTMENT; GRAFT RECIPIENT; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPOTENT STEM CELL; NATURAL KILLER T CELL; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SAFETY; REGENERATIVE STROMAL CELL THERAPY; RELAPSE; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE REGENERATION; TISSUE REPAIR; TREATMENT RESPONSE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; REGENERATIVE MEDICINE; STROMAL CELLS; TRANSPLANTATION CONDITIONING;

EID: 77953618997     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.12.005     Document Type: Review

References (162)

1. Fowler D.H. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 2006, 57:225-244.
2. Pasquini M.C. Impact of graft-versus-host disease on survival. Best Pract Res Clin Haematol 2008, 21:193-204.
3. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
4. Auletta J.J., Cooke K.R. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease. Curr Opin Pediatr 2009, 21:30-38.
5. Shlomchik W.D. Graft-versus-host disease. Nat Rev Immunol 2007, 7:340-352.
6. Duran-Struuck R., Reddy P. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2008, 85:303-308.
7. Toubai T., Sun Y., Reddy P. GVHD pathophysiology: is acute different from chronic?. Best Pract Res Clin Haematol 2008, 21:101-117.
8. Biedermann B.C. Vascular endothelium and graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:129-138.
9. Krenger W., Hollander G.A. The thymus in GVHD pathophysiology. Best Pract Res Clin Haematol 2008, 21:119-128.
10. Cooke K.R., Yanik G. Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease?. Bone Marrow Transplant 2004, 34:753-765.
11. Woywodt A., Haubitz M., Buchholz S., Hertenstein B. Counting the cost: markers of endothelial damage in hematopoietic stem cell transplantation. Bone Marrow Transplant 2004, 34:1015-1023.
12. Bolinger B., Krebs P., Tian Y., et al. Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen. Blood 2008, 111:4588-4595.
13. Reddy P., Negrin R., Hill G.R. Mouse models of bone marrow transplantation. Biol Blood Marrow Transplant 2008, 14:129-135.
14. Barrett A.J., Le Blanc K. Prophylaxis of acute GVHD: manipulate the graft or the environment?. Best Pract Res Clin Haematol 2008, 21:165-176.
15. Jacobsohn D.A. Acute graft-versus-host disease in children. Bone Marrow Transplant 2008, 41:215-221.
16. Ho V.T., Cutler C. Current and novel therapies in acute GVHD. Best Pract Res Clin Haematol 2008, 21:223-237.
17. Perales M.A., Ishill N., Lomazow W.A., et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007, 40:481-486.
18. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564.
19. Jiang Y., Jahagirdar B.N., Reinhardt R.L., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
20. Majumdar M.K., Thiede M.A., Mosca J.D., Moorman M., Gerson S.L. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998, 176:57-66.
21. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
22. Yanez R., Lamana M.L., Garcia-Castro J., Colmenero I., Ramirez M., Bueren J.A. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006, 24:2582-2591.
23. Bieback K., Kern S., Kluter H., Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004, 22:625-634.
24. Li C., Zhang W., Jiang X., Mao N. Human-placenta-derived mesenchymal stem cells inhibit proliferation and function of allogeneic immune cells. Cell Tissue Res 2007, 330:437-446.
25. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007, 213:341-347.
26. Bruder S.P., Jaiswal N., Haynesworth S.E. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997, 64:278-294.
27. Deans R.J., Moseley A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000, 28:875-884.
28. Digirolamo C.M., Stokes D., Colter D., Phinney D.G., Class R., Prockop D.J. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 1999, 107:275-281.
29. Conget P.A., Minguell J.J. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 1999, 181:67-73.
30. Lazarus H.M., Haynesworth S.E., Gerson S.L., Rosenthal N.S., Caplan A.I. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995, 16:557-564.
31. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
32. Prockop D.J. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 2009, 17:939-946.
33. Jiang Y., Vaessen B., Lenvik T., Blackstad M., Reyes M., Verfaillie C.M. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 2002, 30:896-904.
34. Reyes M., Dudek A., Jahagirdar B., Koodie L., Marker P.H., Verfaillie C.M. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002, 109:337-346.
35. Perry R., Miller D., Deans R. Clinical scale expansion of human pluripotent stem cells. Blood ASH Annu Meet Abstr 2005, 106. Abstract 1060.
36. Mays R.W., van't Hof W., Ting A.E., Perry R., Deans R. Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opin Biol Ther 2007, 7:173-184.
37. Ting A.E., Mays R.W., Frey M.R., Hof W.V., Medicetty S., Deans R. Therapeutic pathways of adult stem cell repair. Crit Rev Oncol Hematol 2008, 65:81-93.
38. Jahagirdar B.N., Verfaillie C.M. Multipotent adult progenitor cell and stem cell plasticity. Stem Cell Rev 2005, 1:53-59.
39. Reyes M., Lund T., Lenvik T., Aguiar D., Koodie L., Verfaillie C.M. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001, 98:2615-2625.
40. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006, 98:1076-1084.
41. Majumdar M.K., Thiede M.A., Haynesworth S.E., Bruder S.P., Gerson S.L. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000, 9:841-848.
42. Haynesworth S.E., Baber M.A., Caplan A.I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996, 166:585-592.
43. Askari A.T., Unzek S., Popovic Z.B., et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003, 362:697-703.
44. Potapova I.A., Brink P.R., Cohen I.S., Doronin S.V. Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. J Biol Chem 2008, 283:13100-13107.
45. Kadereit S., Deeds L.S., Haynesworth S.E., et al. Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer. Stem Cells 2002, 20:573-582.
46. Noort W.A., Kruisselbrink A.B., in't Anker P.S., et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 2002, 30:870-878.
47. Angelopoulou M., Novelli E., Grove J.E., et al. Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol 2003, 31:413-420.
48. Maitra B., Szekely E., Gjini K., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004, 33:597-604.
49. Van't Hof W., Mal N., Huang Y., et al. Direct delivery of syngeneic and allogeneic large-scale expanded multipotent adult progenitor cells improves cardiac function after myocardial infarct. Cytotherapy 2007, 9:477-487.
50. Serafini M., Dylla S.J., Oki M., et al. Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells. J Exp Med 2007, 204:129-139.
51. Kovacsovics-Bankowski M., Mauch K., Raber A., et al. Pre-clinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells. Cytotherapy 2008, 10:730-742.
52. Tolar J., O'Shaughnessy M.J., Panoskaltsis-Mortari A., et al. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood 2006, 107:4182-4188.
53. Lazarus H.M., Koc O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
54. Le Blanc K., Samuelsson H., Gustafsson B., et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007, 21:1733-1738.
55. Koc O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
56. Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110:2764-2767.
57. Pozzi S., Lisini D., Podesta M., et al. Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. Exp Hematol 2006, 34:934-942.
58. Macmillan M.L., Blazar B.R., DeFor T.E., Wagner J.E. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009, 43:447-454.
59. Ning H., Yang F., Jiang M., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22:593-599.
60. Barda-Saad M., Rozenszajn L.A., Ashush H., Shav-Tal Y., Ben Nun A., Zipori D. Adhesion molecules involved in the interactions between early T cells and mesenchymal bone marrow stromal cells. Exp Hematol 1999, 27:834-844.
61. Clave E., Busson M., Douay C., et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 2009, 113:6477-6484.
62. Schwartz R.E., Reyes M., Koodie L., et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest 2002, 109:1291-1302.
63. Aksu A.E., Horibe E., Sacks J., et al. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats. Clin Immunol 2008, 127:348-358.
64. Ringden O., Uzunel M., Sundberg B., et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 2007, 21:2271-2276.
65. Ball L., Bredius R., Lankester A., et al. Third party mesenchymal stromal cell infusions fail to induce tissue repair despite successful control of severe grade IV acute graft-versus-host disease in a child with juvenile myelo-monocytic leukemia. Leukemia 2008, 22:1256-1257.
66. Prockop D.J., Olson S.D. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood 2007, 109:3147-3151.
67. Rasmusson I. Immune modulation by mesenchymal stem cells. Exp Cell Res 2006, 312:2169-2179.
68. Le Blanc K., Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007, 262:509-525.
69. Keating A. How do mesenchymal stromal cells suppress T cells?. Cell Stem Cell 2008, 2:106-108.
70. Duffner U., Lu B., Hildebrandt G.C., et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol 2003, 31:897-902.
71. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8:575-581.
72. Sallusto F., Palermo B., Lenig D., et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999, 29:1617-1625.
73. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006, 177:2080-2087.
74. Jiang X.X., Zhang Y., Liu B., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105:4120-4126.
75. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
76. Beyth S., Borovsky Z., Mevorach D., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005, 105:2214-2219.
77. Li H., Guo Z., Jiang X., Zhu H., Li X., Mao N. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells 2008, 26:2531-2541.
78. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
79. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis C.N., Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24:74-85.
80. Gerosa F., Gobbi A., Zorzi P., et al. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005, 174:727-734.
81. Walzer T., Dalod M., Robbins S.H., Zitvogel L., Vivier E. Natural-killer cells and dendritic cells: " l'union fait la force." Blood 2005, 106:2252-2258.
82. Kovacsovics-Bankowski M., Streeter P.R., Mauch K.A., et al. Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease. Cell Immunol 2009, 255:55-60.
83. Highfill S.L., Kelly R.M., O'Shaughnessy M.J., et al. Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming. Blood 2009, 114:693-701.
84. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 2003, 31:890-896.
85. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
86. Weiss M.L., Anderson C., Medicetty S., et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells 2008, 26:2865-2874.
87. Puissant B., Barreau C., Bourin P., et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005, 129:118-129.
88. Chabannes D., Hill M., Merieau E., et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007, 110:3691-3694.
89. Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
90. Selmani Z., Naji A., Zidi I., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
91. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
92. Nasef A., Chapel A., Mazurier C., et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr 2007, 13:217-226.
93. Groh M.E., Maitra B., Szekely E., Koc O.N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005, 33:928-934.
94. Prevosto C., Zancolli M., Canevali P., Zocchi M.R., Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007, 92:881-888.
95. Sudres M., Norol F., Trenado A., et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006, 176:7761-7767.
96. Badillo A.T., Peranteau W.H., Heaton T.E., Quinn C., Flake A.W. Murine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft-versus-host disease. Br J Haematol 2008, 141:224-234.
97. Nauta A.J., Westerhuis G., Kruisselbrink A.B., Lurvink E.G., Willemze R., Fibbe W.E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006, 108:2114-2120.
98. Prigozhina T.B., Khitrin S., Elkin G., Eizik O., Morecki S., Slavin S. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol 2008, 36:1370-1376.
99. Eliopoulos N., Stagg J., Lejeune L., Pommey S., Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 2005, 106:4057-4065.
100. Tian Y., Deng Y.B., Huang Y.J., Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest 2008, 37:29-42.
101. Ren G., Zhang L., Zhao X., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
102. Polchert D., Sobinsky J., Douglas G., et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008, 38:1745-1755.
103. Min C.K., Kim B.G., Park G., Cho B., Oh I.H. IL-10-transduced bone marrow mesenchymal stem cells can attenuate the severity of acute graft-versus-host disease after experimental allogeneic stem cell transplantation. Bone Marrow Transplant 2007, 39:637-645.
104. Tisato V., Naresh K., Girdlestone J., Navarrete C., Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 2007, 21:1992-1999.
105. Socie G., Blazar B.R. Acute graft-versus-host disease; from the bench to the bedside. Blood 2009, 114:4327-4336.
106. Watanabe H., Numata K., Ito T., Takagi K., Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 2004, 22:460-466.
107. Chung N.G., Jeong D.C., Park S.J., et al. Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol 2004, 80:370-376.
108. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
109. Muller I., Kordowich S., Holzwarth C., et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis 2008, 40:25-32.
110. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
111. Kebriaei P., Isola L., Bahceci E., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
112. von Bonin M., Stolzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
113. Kawai T., Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005, 17:338-344.
114. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
115. Nagai Y., Garrett K.P., Ohta S., et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006, 24:801-812.
116. Holl T.M., Kelsoe G. Outside influence: TLRs direct hematopoietic cell fates. Immunity 2006, 24:667-669.
117. Pevsner-Fischer M., Morad V., Cohen-Sfady M., et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007, 109:1422-1432.
118. Hwa Cho H., Bae Y.C., Jung J.S. Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 2006, 24:2744-2752.
119. Takeda K., Akira S. Toll-like receptors in innate immunity. Int Immunol 2005, 17:1-14.
120. Harter L., Mica L., Stocker R., Trentz O., Keel M. Increased expression of toll-like receptor-2 and -4 on leukocytes from patients with sepsis. Shock 2004, 22:403-409.
121. Armstrong L., Medford A.R., Hunter K.J., Uppington K.M., Millar A.B. Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol 2004, 136:312-319.
122. Siren J., Pirhonen J., Julkunen I., Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 2005, 174:1932-1937.
123. De Rycke L., Vandooren B., Kruithof E., De Keyser F., Veys E.M., Baeten D. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005, 52:2146-2158.
124. An H., Xu H., Yu Y., et al. Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-kappaB, ERK and p38 MAPK signal pathways. Immunol Lett 2002, 81:165-169.
125. Hornung V., Rothenfusser S., Britsch S., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
126. Shi L., Wang J.S., Liu X.M., Hu X.Y., Fang Q. Upregulated functional expression of Toll like receptor 4 in mesenchymal stem cells induced by lipopolysaccharide. Chin Med J (Engl) 2007, 120:1685-1688.
127. Asehnoune K., Strassheim D., Mitra S., Kim J.Y., Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 2004, 172:2522-2529.
128. Bhattacharyya J., Biswas S., Datta A.G. Mode of action of endotoxin: role of free radicals and antioxidants. Curr Med Chem 2004, 11:359-368.
129. Chauveau C., Remy S., Royer P.J., et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 2005, 106:1694-1702.
130. Xia Z.W., Zhong W.W., Xu L.Q., et al. Heme oxygenase-1-mediated CD4+CD25high regulatory T cells suppress allergic airway inflammation. J Immunol 2006, 177:5936-5945.
131. Ryter S.W., Alam J., Choi A.M. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 2006, 86:583-650.
132. Gerbitz A., Ewing P., Wilke A., et al. Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2004, 10:461-472.
133. Thimmulappa R.K., Lee H., Rangasamy T., et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006, 116:984-995.
134. Liby K., Hock T., Yore M.M., et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005, 65:4789-4798.
135. Sun K., Li M., Konopleva M., et al. The synthetic triterpenoid, CDDO, suppresses alloreactive T cell responses and reduces murine early acute graft-versus-host disease mortality. Biol Blood Marrow Transplant 2007, 13:521-529.
136. Yu S., Cho H.H., Joo H.J., Bae Y.C., Jung J.S. Role of MyD88 in TLR agonist-induced functional alterations of human adipose tissue-derived mesenchymal stem cells. Mol Cell Biochem 2008, 317:143-150.
137. Liotta F., Angeli R., Cosmi L., et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008, 26:279-289.
138. Tomchuck S.L., Zwezdaryk K.J., Coffelt S.B., Waterman R.S., Danka E.S., Scandurro A.B. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008, 26:99-107.
139. Opitz C.A., Litzenburger U.M., Lutz C., et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009, 27:909-919.
140. Chan J.L., Tang K.C., Patel A.P., et al. Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006, 107:4817-4824.
141. Krampera M., Cosmi L., Angeli R., et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006, 24:386-398.
142. Ryan J.M., Barry F., Murphy J.M., Mahon B.P. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007, 149:353-363.
143. Francois M., Romieu-Mourez R., Stock-Martineau S., Boivin M.N., Bramson J.L., Galipeau J. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen presenting cell properties. Blood 2009, 114:2632-2638.
144. Romieu-Mourez R., Francois M., Boivin M.N., Bouchentouf M., Spaner D.E., Galipeau J. Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009, 182:7963-7973.
145. Nemeth K., Leelahavanichkul A., Yuen P.S., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009, 15:42-49.
146. Spaeth E., Klopp A., Dembinski J., Andreeff M., Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008, 15:730-738.
147. Sordi V., Malosio M.L., Marchesi F., et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106:419-427.
148. Devine S.M., Cobbs C., Jennings M., Bartholomew A., Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003, 101:2999-3001.
149. Klopp A.H., Spaeth E.L., Dembinski J.L., et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007, 67:11687-11695.
150. Ruster B., Gottig S., Ludwig R.J., et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006, 108:3938-3944.
151. Son B.R., Marquez-Curtis L.A., Kucia M., et al. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-CXCR4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells 2006, 24:1254-1264.
152. Marinova-Mutafchieva L., Williams R.O., Funa K., Maini R.N., Zvaifler N.J. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 2002, 46:507-513.
153. Croitoru-Lamoury J., Lamoury F.M., Zaunders J.J., Veas L.A., Brew B.J. Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone. J Interferon Cytokine Res 2007, 27:53-64.
154. Fang L., Lange C., Engel M., Zander A.R., Fehse B. Sensitive balance of suppressing and activating effects of mesenchymal stem cells on T-cell proliferation. Transplantation 2006, 82:1370-1373.
155. Djouad F., Plence P., Bony C., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
156. Sackstein R. Glycosyltransferase-programmed stereosubstitution (GPS) to create HCELL: engineering a roadmap for cell migration. Immunol Rev 2009, 230:51-74.
157. Cooke K.R., Jannin A., Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:23-32.
158. Woda J., Lehman N., Cutrone R., et al. MAPCs modulate endotherial cell adhesion molecule cell surface expression following activation and reduce inflammation following AMI in rats. Basic Cardiovasc Sci Annu Conf 2009, Abstract.
159. Austrup F., Vestweber D., Borges E., et al. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflammed tissues. Nature 1997, 385:81-83.
160. Ohmori K., Fukui F., Kiso M., et al. Identification of cutaneous lymphocyte-associated antigen as sialyl 6-sulfo Lewis X, a selectin ligand expressed on a subset of skin-homing helper memory T cells. Blood 2006, 107:3197-3204.
161. Fang B., Song Y., Liao L., Zhang Y., Zhao R.C. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007, 39:3358-3362.
162. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.